In this article, Drs. Lawrence Eichenfield and Jessica Sprague review some of the most significant findings and developments in pediatric dermatology from the last year beginning with the availability of biologic agents for pediatric psoriasis and atopic dermatitis.
The first patient has been dosed in the phase two study of PR022 (hypochlorous acid, Realm Therapeutics), a topical gel treatment for patients with atopic dermatitis.
Moisturizers were described as the “cornerstone of therapy” in atopic dermatitis in the 2014 AAD guidelines for topical therapies in atopic dermatitis, but the products differ greatly by ingredients which can improve the condition or make it worse.
A small study finds that the combination of methotrexate and azathioprine is safe and effective as maintenance treatment for patients with moderate-to-severe atopic dermatitis for up to five years.
In this slideshow, we summarize the phenotypes associated with childhood atopic dermatitis as addressed recently in JAMA Pediatrics.
Treatment for atopic dermatitis isn’t always straightforward. In this article, a physician outlines treatment approaches.
In this article, we take a look at the development of new treatments for atopic dermatitis.
Atopic dermatitis patients have a phobia of topical corticosteroids that is so strong, it’s been described as a “phenomenon.”
A pilot study shows that Manuka honey may have some healing properties in atopic dermatitis.
Patch testing for allergic contact dermatitis in the pediatric population is performed at a higher rate than previously reported, but still grossly underreported, according to a study of the Pediatric Contact Dermatitis Registry.